Frontier and hotspot of biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer
- VernacularTitle:预测非小细胞肺癌免疫治疗疗效生物标志物的研究前沿与热点分析
- Author:
Lei YUAN
1
;
Zhiming SHEN
1
;
Fei SUN
1
;
Yibo SHAN
1
;
Yi LU
1
;
Jianwei ZHU
1
;
Hongcan SHI
1
Author Information
1. Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Institute of Translational Medicine, Medical College of Yangzhou University, Clinical Medical College of Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
immunotherapy;
biomarkers;
CiteSpace;
visualization analysis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(04):562-569
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the current development of researches on biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer and to provide reference for subsequent studies. Methods Studies on biomarkers for predicting the efficacy of immunotherapy for non-small cell lung cancer indexed in the Web of Science Core Collection from 2017 to 2021 were searched by computer. The annual distribution, journals, authors, countries, institutions, and keywords of studies were visualized and analyzed by CiteSpace. Results A total of 426 studies were collected, including 298 articles and 128 reviews. The average number of published studies was about 85, and increased year by year. PD-L1 expression, tumor mutational burden, tumor microenvironment and liquid biopsy were hot keywords in this field. Conclusion In the future, combination of biomarkers in the liquid biopsy and tumor microenvironment with radiomics analysis will be the research hotspot and frontier in this field for more accurate assessment with tumor-related signatures such as lymphocytic immune status and characteristics of tumor lesions in non-small cell lung cancer patients.
